Novel conjugates &lt;modified nucleoside &ndash; nanoparticle&gt; to suppress the growth of superbugs

Negrya S.; Efremenkova O.; Artemyev M.; Sizova S.; Oleinikov V.; Alexandrova L.

Articolul precedent

Articolul urmator

736

Ultima descărcare din IBN:
2022-01-15 19:04

SM ISO690:2012

NEGRYA, S., EFREMENKOVA, O., ARTEMYEV, M., SIZOVA, S., OLEINIKOV, V., ALEXANDROVA, L.. Novel conjugates <modified nucleoside – nanoparticle> to suppress the growth of superbugs. In: NANO-2019: Limits of Nanoscience and Nanotechnologies, Ed. 2019, 24-27 septembrie 2019, Chişinău. Chișinău, Republica Moldova: 2019, p. 64.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

NANO-2019: Limits of Nanoscience and Nanotechnologies 2019

Conferința "SPINTECH Summer school “S/F Hybrid Structures for Spintronics”"
2019, Chişinău, Moldova, 24-27 septembrie 2019

Novel conjugates <modified nucleoside – nanoparticle> to suppress the growth of superbugs

Pag. 64-64

Negrya S.¹, Efremenkova O.², Artemyev M.³⁴, Sizova S.³, Oleinikov V.³, Alexandrova L.¹

¹ Engelhardt Institute of Molecular Biology RAS,
² Gause Institute of New Antibiotics,
³ Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS,
⁴ Research Institute for Physical Chemical Problems, Belarusian State University

Disponibil în IBN: 27 ianuarie 2020

Descarcă PDF

Rezumat

Nowadays practically all pathogenic bacteria and viruses have developed resistance to most clinically important medicinal preparations, hence, there is a need in new drugs acting on new targets and being active against superbugs - resistant strains of pathogens [1]. Recently we have synthesized 2’-deoxypyrimidine nucleoside derivatives bearing extended alkyloxymethyl or alkyl(1,2,3-triazol-1-yl)methyl substituents at С-5 position and demonstrated their effective bacteriostatic activity against two Mycobacterium tuberculosis strains [2] as well as against a set of Gram-positive bacteria [3]. However, the nucleosides with large hydrophobic fragments are insoluble in water, thus, limiting the biological investigations. To solve this problem, a linker group was introduced for coupling a nucleoside moiety to a nanoparticle. At the same time, we have developed fundamentally new nanostructures of the type “Plates” with both positive and negative surface charge [5] with uniquely high optical properties (narrow fluorescence peak, high extinction, high efficiency of two-photon excitation) and offered an efficient method for obtaining conjugates [nucleoside-nanoparticle]. To study the effect of nanostructures on bacterial cells were selected bacteria that differ in shape, structure and thickness of the cell wall. Herein we will present a new approach for transporting medicinal agents into bacterial cells to their targets, namely, the preparation of conjugates of biologically active nucleosides with nanoparticles.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-92954</cfResPublId>
<cfResPublDate>2019</cfResPublDate>
<cfStartPage>64</cfStartPage>
<cfISBN></cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/92954</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Novel conjugates &lt;modified nucleoside &ndash; nanoparticle&gt; to suppress the growth of superbugs</cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Nowadays practically all pathogenic bacteria and viruses have developed resistance to most clinically important medicinal preparations, hence, there is a need in new drugs acting on new targets and being active against superbugs - resistant strains of pathogens [1]. Recently we have synthesized 2&rsquo;-deoxypyrimidine nucleoside derivatives bearing extended alkyloxymethyl or alkyl(1,2,3-triazol-1-yl)methyl substituents at С-5 position and demonstrated their effective bacteriostatic activity against two Mycobacterium tuberculosis strains [2] as well as against a set of Gram-positive bacteria [3]. However, the nucleosides with large hydrophobic fragments are insoluble in water, thus, limiting the biological investigations. To solve this problem, a linker group was introduced for coupling a nucleoside moiety to a nanoparticle. At the same time, we have developed fundamentally new nanostructures of the type &ldquo;Plates&rdquo; with both positive and negative surface charge [5] with uniquely high optical properties (narrow fluorescence peak, high extinction, high efficiency of two-photon excitation) and offered an efficient method for obtaining conjugates [nucleoside-nanoparticle]. To study the effect of nanostructures on bacterial cells were selected bacteria that differ in shape, structure and thickness of the cell wall. Herein we will present a new approach for transporting medicinal agents into bacterial cells to their targets, namely, the preparation of conjugates of biologically active nucleosides with nanoparticles.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-71798</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-71799</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-71800</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-71801</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-71802</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-71803</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-71798</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-71798-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Negrya</cfFamilyNames>
<cfFirstNames>S.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-71799</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-71799-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Efremenkova</cfFamilyNames>
<cfFirstNames>O.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-71800</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-71800-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Artemyev</cfFamilyNames>
<cfFirstNames>M.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-71801</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-71801-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Sizova</cfFamilyNames>
<cfFirstNames>S.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-71802</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-71802-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Oleinikov</cfFamilyNames>
<cfFirstNames>V.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-71803</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-71803-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Alexandrova</cfFamilyNames>
<cfFirstNames>L.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>